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Background: MicroRNA-23a (miR-23a) has been demonstrated to play an important role in the development of
several types of cancer, but its role in tumorigenesis of laryngeal carcinoma is still unclear. The aim of this study
was to investigate the expression patterns and clinical implications of miR-23a in laryngeal cancer.
Methods: Quantitative RT-PCR was performed to evaluate the expression level of miR-23a in 52 pairs of laryngeal
cancer. Analysis between miR-23a expression and clinical features of laryngeal carcinomas was performed by
appropriate statistical methods. Role of miR-23a in laryngeal cancer cell migration and invasion was detected
via transwell and matrigel assays, respectively.
Results: miR-23a was significantly up-regulated in laryngeal cancer tissues compared to normal adjacent laryngeal
tissues (P < 0.01). Tumors with high miR-23a expression had significantly greater extent of lymph node metastasis
(P < 0.01), worse clinical stage (P < 0.05) and shorter overall five-year survival (P < 0.01) than those with low miR-23a
expression. Both univariate and multivariate Cox hazard regression analysis results showed that clinical stage and
miR-23a expression were significantly correlated with patient five-year survival (P < 0.01). miR-23a overexpression also
significantly promoted laryngeal cancer cell migration and invasion in vitro.
Conclusions: miR-23a, an independent prognostic factor for laryngeal cancer, participates in the onset and progression
of laryngeal cancer.
Virtual slides: The virtual slide(s) for this article can be found here: http://www.diagnosticpathology.diagnomx.eu/vs/
2021488014982305
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At present, the invasion and metastasis of tumor cells
are considered as major causes of mortality in cancer pa-
tients [1]. According to the survey, the survival rate of
laryngeal carcinoma patients with metastasis is only
30%–40% [2]. Although some tumor biomarkers such as
carcinoembryonic antigen (CEA), carbohydrate antigen
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unless otherwise stated.tumors metastasis [3], there is still lack of ideal bio-
markers for predicting invasion and metastasis of cancer
patients.
MicroRNAs (miRNAs) are a category of small (19 ~ 24
nucleotides), non-coding and single-stranded endogen-
ous RNA molecules that influence multiple biological
events, especially the development and progress of ma-
lignancies [4-7]. Some studies have reported that miRNA
could be used as a biomarker for the invasion and me-
tastasis of several types of cancer [8-12]. However, the
expression patterns and role of miRNAs in laryngeal car-
cinoma are seldom reported in the literature.
MiR-23a is aberrantly expressed in many cancers such
as breast cancer, colorectal cancer, lung cancer, gastricThis is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,

















Note: F and R indicates forward and reverse primers, respectively. NC shows
the negative control.
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of apoptosis and proliferation [13-18]. Similar to our re-
cent work, miR-23a promotes proliferation and represses
apoptosis in laryngeal squamou cell cancer (LSCC) (un-
published observations) and pancreatic cancer through
directly targeting the APAF-1 3′UTR [19]. Also, miR-23a
has been demonstrated to participate in regulation of inva-
sion and metastasis in some cancers such as colorectal
carcinoma and neuroblastoma [15,20]. Li et al. discovered
a series of differentially expressed miRNAs including
miRNA-23a in formalin-fixed paraffin-embedded laryngeal
carcinoma tissues and the paired normal controls based
on the miRNA microarray and found that miRNA-23a is
associated with the lymphatic metastasis of laryngeal car-
cinoma [21]. However, the role of miR-23a in invasion and
metastasis of laryngeal carcinoma is still unclear.
In the study, the miR-23a gene expression in laryngeal
carcinoma tissues was detected by Quantitative RT-PCR.
Correlations of miR-23a to survival and clinic-pathological
features of LSCC patients were analyzed. Prognostic fac-
tors related to LSCC were revealed by univariate and
multivariate analysis. Role of miR-23a in invasion and me-
tastasis of Hep-2 (human laryngeal cancer) cells was also
evaluated by matrigel and transwell assays, respectively.
Methods
Patients and tissue samples
This study was approved by the Research Ethics Committee
of China Medical University (Shenyang, China) and the
463th Hospital of PLA (Shenyang, China). Written in-
formed consent was obtained from all patients. All speci-
mens were handled and made anonymous according to the
ethical and legal standards.
Fifty-two pairs of laryngeal carcinoma tissue and
paired adjacent normal tissue were obtained from each
patient who underwent surgical resection treatment at the
463th Hospital of PLA (Shenyang, China) between 1999
and 2011, and were subsequently diagnosed based on
histopathological evaluation. Normal laryngeal mucosa
specimens were retrieved 10 mm outside the negative
margin. Samples were placed in RNAlater Tissue Protect
Tubes (Qiagen, Hilden, Germany) and stored at −80°C.
Postsurgical pathology confirmed the diagnosis of squa-
mous cell carcinoma in all patients. All patients did not re-
ceive radio- or chemotherapy before surgery.
Cell culture and transfection
Hep-2 cell lines obtained from the Cell Biology Institute
of Shanghai, Chinese Academy of Science were main-
tained in RPMI 1640 (GIBCO, Los Angeles, CA)
medium supplemented with 10% fetal bovine serum
(Hyclone, Logan, USA), 100 units/ml penicillin and
100 μg/ml streptomycin in a humidified atmosphere at
37°C with 5% CO2.For transfection assay, Hep-2 cells were transfected
with miR-23a inhibitor, inhibitor negative control, miR-
23a mimic and miR-23a mimic negative control, respect-
ively, by using Lipofectamine™2000 reagent (Invitrogen,
Carlsbad, CA) according to the manufacturer’s instruc-
tions. All the nucleotide sequences used in the study are
shown in Table 1.
RNA extraction, reverse transcription and quantitative
RT-PCR
Total RNA was extracted from the corresponding tissues
using a miRcute miRNA isolation kit (Tiangen, Bejing,
China) according to the manufacturer’s instructions. Re-
verse transcription was performed using the One Step
Prime Script miRNA cDNA Synthesis Kit (Takara,
Dalian, China) following the manufacturer’s instructions.
Quantitative RT-PCR was performed using SYBR® Pre-
mix Ex Taq™ II (Takara, Dalian, China) according to the
manufacturer’s instructions with the 7500 real-time RT-
PCR system (Applied Biosystems, Foster City). U6B was
used as the normalization control. Each detection was
performed in triplicate.
Migration and invasion assays
Hep-2 Cells were suspended in serum-free medium. For
migration and invasion assays, non-coated and Matrigel-
coated membranes (24-well insert; 8-μm pore size;
Corning Costar Corp) were used, respectively. The
Matrigel-coated membrane was prepared with 30 μl
Matrigel (BD Biosciences, San Jose, CA) and incubated
for 40 min at 37°C in advance. In details, 1 × 105 cells
were plated in the top chamber with the non-coated and
Matrigel-coated membranes, respectively. Medium sup-
plemented with serum was used as a chemoattractant in
Figure 1 miR-23a expression is associated with lymph node metastasis and survival rate in LSCC. (A) Relative miR-23a expression in 52
LSCC patients. The relative expression was calculated as the ratio of miR-23a in cancer tissue to that in paired adjacent tissue in each case. The
digit on the X-axis shows the number of samples used in the study. (B) General miR-23a expression in LSCC. T and R are cancer and matched
adjacent tissues, respectively. miR-23a was normalized by U6 RNA. Symbol *indicates P < 0.05. (C) miR-23a expression in LSCC with lymph node
metastasis. T and R are cancer and matched adjacent tissues, respectively. miR-23a was normalized by U6 RNA. *indicates P < 0.05, n = 18.
(D) miR-23a expression in cancer and paired tissues in different survival groups. T and R are cancer and matched adjacent tissues, respectively. miR-23a
was normalized by U6 RNA. *indicates P < 0.05, n = 37 in survival less than 5-year group and n = 15 in survival more than 5-year group. (E) miR-23a
expression in cancer tissues in different survival groups. miR-23a was normalized by U6 RNA. *indicates P < 0.05, n = 52. (F) Postoperative 5-year survival
curves of LSCC patients correlated to miR-23a expression. Kaplan–Meier estimates of overall 5-year survival for the LSCC patients with low miR-23a
expression (fold change≤ 2) and high miR-23a expression (fold change >2), respectively. The P value was calculated using the Log-rank test between
patients with low and high miR-23a expression.
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Table 2 Association between miR-23a and
clinicopathological characteristics in 52 patients with LSCC
Features No.of cases miR-23a expression P-value
Age
<60 22 3.87 ± 4.50 0.234
≥60 30 6.35 ± 10.00
Gender
male 45 5.17 ± 7.85 0.543
female 7 3.32 ± 2.27
Smoking
Nonsmokers 7 3.48 ± 5.36 0.584
Current smokers 45 5.14 ± 7.65
Drinking
drinker 37 5.54 ± 8.31 0.346
nondrinker 15 3.39 ± 4.08
Differentiation
well 15 3.06 ± 2.25 0.251
Moderate 29 4.91 ± 8.43
Poor 8 8.46 ± 8.88
Lymph node
Negative 34 2.93 ± 3.72 0.006*
Positive 18 8.67 ± 10.63
Tumor depth (pT)
T1 9 2.52 ± 2.17 0.226
T2 15 3.37 ± 5.95
T3 15 4.97 ± 5.77
T4 13 8.31 ± 11.29
Clinical stage
I 6 2.04 ± 1.67 0.011*
II 12 1.88 ± 1.67
III 31 5.54 ± 6.6
IV 3 16.44 ± 20.48
One-way ANOVO was used to analyze the correlation between the expression
of miR-23a and clinicopathological features of the patients. *indicates P <0.05.
Table 3 Univariate and multivariate Cox hazard
regression analysis for prognostic factors








Male vs female 1.349(0.458-3.973) 0.587
Age

























IVvs IIIvs IIvsI 5.513(2.300-13.214) P < 0.001* 6.998(2.217-22.083)
miR-23a
expression
High vs low 7.419(2.561-21.491) P < 0.001* 6.712(2.076-21.700)
*indicatesP < 0.05.
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37°C in a 5% CO2 incubator and those that did not mi-
grate or invade through the pores were removed by a
cotton swab. Cells on the lower surface of the membrane
were then fixed with methanol, stained with hematoxylin
and eosin, and subjected to microscopic inspection and
photographed. Values for migration and invasion were
obtained by counting five fields per membrane and each
experiment was performed at least three times.
Statistical analysis
SPSS16.0 software for Windows (SPSS Inc, IL, USA) was
used for statistical analysis. Data were expressed as the
mean ± standard deviation (SD). The differentialexpression of miR-23a between laryngeal cancer and the
matched adjacent mucosa was evaluated by paired sam-
ple t-test. χ2 test was used to analyze association of miR-
23a with survival. One-way ANOVO was applied to
evaluate the relationship between miR-23a expression
and the clinic-pathologic characteristics. Kaplan–Meier
method was used for survival analysis. Difference in sur-
vival was estimated using the log-rank test. Risk factors
for LSCC were examined by univariate and multivariate
analyses (Cox proportional hazards regression model).
P < 0.05 was considered statistically significant.
Results
Increased miR-23a expression participates in laryngeal
carcinogenesis
miR-23a expression was detected in 52 pairs of laryngeal
cancer tissue and the matched adjacent tissue by qRT-
PCR. As showed in Figure 1A, miR-23a level was in-
creased in 37 out of 52 (71.2%) laryngeal cancer tissues
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nificantly up-regulated in laryngeal cancer tissues com-
pared with normal counterpart (P < 0.05) (Figure 1B),
suggesting that miR-23a takes part in the genesis of la-
ryngeal cancer.
High miR-23a level contributes to poor prognosis in
patients with laryngeal carcinomas
In 18 cases of patients with lymph nodes metastasis,
miR-23a was significantly up-regulated in laryngeal can-
cer tissues compared to the normal counterpart (P <
0.05) (Figure 1C; Table 2). In patients aged less than
5 years after operation, miR-23a expression level was sig-
nificantly higher in cancer tissues than that in controls
(P < 0.05) (Figure 1D). miR-23a average level in cancer
tissues was at higher level in patients aged less than
5 years, which showed a significant difference comparedFigure 2 miR-23a promotes the Hep-2 cell migration and invasion. (A
membrane. (B) Representative fields of invasive cells on the underside of m
independent experiments. *indicates P <0.05.to that in patients aged more than 5 years (P < 0.05)
(Figure 1E). These results imply that miR-23a expression
level correlates with lymph nodes metastasis and pa-
tients’ survival in laryngeal cancer.
To better understand the potential roles of miR-23a in
LSCC development and progression, one-way ANOVO
was used to determine the relationships of miR-23a with
various clinical features of LSCC, including age, gender,
smoking, drinking, lymph nodes metastasis, differenti-
ation, and clinic-pathological stage. As shown in Table 2,
miR-23a overexpression in tumor tissues was strongly as-
sociated with lymph node metastasis and advanced clinical
stage of LSCC (P = 0.006 and P = 0.011, respectively).
We then used Kaplan–Meier method, log-rank test and
Cox proportional hazard regression model to analyze the
survival correlation of LSCC patients with miR-23a ex-
pression and clinic-pathological features. Up-regulated) Representative fields of migrated cells on the underside of
embrane. Data are presented as mean ± SD of at least three
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sion. As indicated in Figure 1F, high miR-23a level was
correlated with shorter overall five-year survival of LSCC
patients (log-rank test: P = 0.003). Univariate Cox hazard
regression analysis results showed that LSCC patient sur-
vival was significantly correlated with tumor depth, lymph
node metastasis, clinical stage and miR-23a expression.
However, only clinical stage and miR-23a expression were
significantly correlated with patient survival after multi-
variate analysis was performed (Table 3).
miR-23a promotes cell migration and invasion in
laryngeal cancer Hep-2 cells
To confirm the role of miR-23ain laryngeal cancer me-
tastasis, we examined the effect of miR-23aon laryngeal
cancer cell migration and invasion in vitro. As results,
both migrated and invaded cells significantly increased
and decreased in miR-23a mimic and miR-23a inhibitor
groups compared to the controls, respectively, implying
that miR-23a promotes laryngeal cancer cell migration
and invasion (Figure 2).
Discussion
Several genes, such as P53, HER2 and Bcl-2, are consid-
ered to be tissue biomarkers for the early diagnosis of
malignant tumor or assessing the prognosis of patients
with tumor [22,23]. However, their clinical utility is lim-
ited due to their inexistence in body fluids. It is surpris-
ing that miRNAs are easily detected by qRT-PCR
[24,25]. Moreover, miRNAs are found stable in 12 differ-
ent biological fluids such as plasma, saliva, tears, urine,
amniotic fluid, colostrum, breast milk, bronchial secre-
tions, cerebrospinal fluid, peritoneal fluid, pleural fluid
and seminal fluid [26]. Furthermore, these circulating
miRNAs from different fluids especially from serum and
urine can reflect the state of a given disease, suggesting
that they are useful biomarkers in a broad range of clin-
ical applications in human diseases [27].
In the study, we found miR-23a was significantly up-
regulated in laryngeal carcinoma tissues compared to the
adjacent tissues, which is consistent with previous findings
in most solid tumors such as colon carcinoma, lung cancer
and neuroblastoma, respectively [15,16,20]. In contrast,
miR-23a is found to be down-regulated in chronic or acute
leukemia [10,28] , respectively. Nevertheless, the abnormal
miR-23a expression plays a critical role in carcinogenesis.
In addition, we found that the miR-23a gene expres-
sion in laryngeal carcinoma patients with lymph node
metastasis is significantly higher than that in patients
without lymph node metastasis. The result is consistent
with previous report [21]. Our results also indicated that
high level of miR-23a correlates with LSCC clinical stages,
suggesting that miR-23a participates in laryngeal cancer
cell migration and invasion, which is confirmed in vitro inthe study. These results are in line with previous findings
in colorectal cancer and neuroblastoma [15-20].
The overall five-year survival of laryngeal cancer pa-
tients has not improved (at approximately 35–70%).
Conversely, it decreases in the United state [29,30].
Therefore, there is a great need to identify new bio-
markers for the diagnosis and prognosis of laryngeal
carcinoma. Our present study demonstrated that high
miR-23a level in laryngeal cancer tissues significantly cor-
relates with poorer five-year survival, which is reconfirmed
by our multivariate Cox hazard regression analysis, imply-
ing that miR-23a expression level is an independent prog-
nostic factor for laryngeal cancer in addition to clinical
stage. Similar result is also found in liver cancer [31]. In
addition to miR-23a, we also found that clinical stage is
also related to poor progression in LSCC.
In the future, our work will focus on the molecular
mechanism of miR-23a in laryngeal cancer cell migration
and invasion.
Conclusion
miR-23a is an independent prognostic factor for laryn-
geal cancer and participates in the onset and progression
of laryngeal cancer.
Abbreviations
LSCC: Laryngeal squamou cell cancer; miRNA: microRNA; UTR: Untranslation
region.
Competing interests
The authors declare that they have no competing interests.
Authors’ contributions
XW carried out qRT-PCR and participated in the statistical analysis and
drafted the manuscript. N carried out migration detection. S carried out
invasion assay. Y and ZX participated in qRT-PCR assays. YY participated in
migration and invation assays. GB participated in the design of the study
and the statistical analysis. WN participated in the design of the study and
revised the manuscript. All authors read and approved the final manuscript.
Authors’ information
XW, N, S, Y, ZX and YY are post-graduate students. GB is a director of Laboratory
Medicine Department, No. 202 Hospital of PLA. WN is an associate director of
Medical Genetics Department of China Medical University.
Acknowledgements
This work was supported by the National Natural Science Foundation of
China (81172577 and 81372876). We thank professor Bao-Shen Zhou (Depart-
ment of Epidemiology, China medical University) to give us an advice on
statistical analysis.
Received: 14 November 2014 Accepted: 25 March 2015
References
1. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer
statistics. CA Cancer J Clin. 2011;61:69–90.
2. Gourin CG, Conger BT, Sheils WC, Bilodeau PA, Coleman TA, Porubsky ES.
The effect of treatment on survival in patients with advanced laryngeal
carcinoma. Laryngoscope. 2009;119:1312–7.
3. Shibutani M, Maeda K, Nagahara H, Ohtani H, Sakurai K, Toyokawa T, et al.
Significance of CEA and CA19-9 combination as a prognostic indicator and
for recurrence monitoring in patients with stage II colorectal cancer.
Anticancer Res. 2014;34:3753–8.
Zhang et al. Diagnostic Pathology  (2015) 10:22 Page 7 of 74. Lages E, Ipas H, Guttin A, Nesr H, Berger F, Issartel JP. MicroRNAs: molecular
features and role in cancer. Front Biosci (Landmark Ed). 2012;17:2508–40.
5. Doench JG, Sharp PA. Specificity of microRNA target selection in
translational repression. Genes Dev. 2004;18:504–11.
6. Croce CM, Calin GA. miRNAs, cancer, and stem cell division. Cell. 2005;122:6–7.
7. Ambros V. The functions of animal microRNAs. Nature. 2004;431:350–5.
8. Sun X, Liu Z, Yang Z, Xiao L, Wang F, He Y, et al. Association of microRNA-126
expression with clinicopathological features and the risk of biochemical
recurrence in prostate cancer patients undergoing radical prostatectomy.
Diagn Pathol. 2013;8:208.
9. Su ZX, Zhao J, Rong ZH, Geng WM, Wu YG, Qin CK. Upregulation of
microRNA-25 associates with prognosis in hepatocellular carcinoma.
Diagn Pathol. 2014;9:47.
10. Zhu X, Lin Z, Du J, Zhou X, Yang L, Liu G. Studies on microRNAs that are
correlated with the cancer stem cells in chronic myeloid leukemia. Mol Cell
Biochem. 2014;390:75–84.
11. Han ZB, Chen HY, Fan JW, Wu JY, Tang HM, Peng ZH. Up-regulation of
microRNA-155 promotes cancer cell invasion and predicts poor survival of
hepatocellular carcinoma following liver transplantation. J Cancer Res Clin
Oncol. 2012;138:153–61.
12. Yu J, Wang Y, Dong R, Huang X, Ding S, Qiu H. Circulating microRNA-218
was reduced in cervical cancer and correlated with tumor invasion. J Cancer
Res Clin Oncol. 2012;138:671–4.
13. Li X, Liu X, Xu W, Zhou P, Gao P, Jiang S, et al. c-MYC-regulated miR-23a/24-2/
27a cluster promotes mammary carcinoma cell invasion and hepatic
metastasis by targeting Sprouty2. J Biol Chem. 2013;288:18121–33.
14. Yong FL, Wang CW, Roslani AC, Law CW. The involvement of miR-23a/
APAF1 regulation axis in colorectal cancer. Int J Mol Sci. 2014;15:11713–29.
15. Jahid S, Sun J, Edwards RA, Dizon D, Panarelli NC, Milsom JW, et al. miR-23a
promotes the transition from indolent to invasive colorectal cancer.
Cancer Discov. 2012;2:540–53.
16. Cao M, Li Y, Lu H, Meng Q, Wang L, Cai L, et al. miR-23a-mediated
migration/invasion is rescued by its target, IRS-1, in non-small cell lung
cancer cells. J Cancer Res Clin Oncol. 2014;140:1661–70.
17. Liu X, Liu Q, Fan Y, Wang S, Liu X, Zhu L, et al. Downregulation of PPP2R5E
expression by miR-23a suppresses apoptosis to facilitate the growth of
gastric cancer cells. FEBS Lett. 2014;588:3160–9.
18. Lian S, Shi R, Bai T, Liu Y, Miao W, Wang H, et al. Anti-miRNA-23a
oligonucleotide suppresses glioma cells growth by targeting apoptotic
protease activating factor-1. Curr Pharm Des. 2013;19:6382–9.
19. Liu N, Sun YY, Zhang XW, Chen S, Wang Y, Zhang ZX, et al. Oncogenic miR-23a
in Pancreatic Ductal Adenocarcinogenesis Via Inhibiting APAF1. Dig Dis Sci.
2015 Feb 21, Online.
20. Cheng L, Yang T, Kuang Y, Kong B, Yu S, Shu H, et al. MicroRNA-23a
promotes neuroblastoma cell metastasis by targeting CDH1. Oncol Let.
2014;7:839–45.
21. Li L, Zhang ZM, Liu Y, Wei MH, Xue LY, Zou SM, et al. DNA microarrays-based
microRNA expression profiles derived from formalin-fixed paraffin-embedded
tissue blocks of squammous cell carcinoma of larynx. Zhonghua Bing Li Xue Za
Zhi. 2010;39:391–5.
22. Nishimura R, Osako T, Okumura Y, Tashima R, Toyozumi Y, Arima N.
Changes in the ER, PgR, HER2, p53 and Ki-67 biological markers between
primary and recurrent breast cancer: discordance rates and prognosis.
World J Surg Oncol. 2011;9:131.
23. Zhao L, Yu N, Guo T, Hou Y, Zeng Z, Yang X, et al. Tissue biomarkers for
prognosis of prostate cancer: a systematic review and meta-analysis.
Cancer Epidemiol Biomarkers Prev. 2014;23:1047–54.
24. Grasedieck S, Sorrentino A, Langer C, Buske C, Döhner H, Mertens D, et al.
Circulating microRNAs in hematological diseases: principles, challenges, and
perspectives. Blood. 2013;121:4977–84.
25. Allegra A, Alonci A, Campo S, Penna G, Petrungaro A, Gerace D, et al.
Circulating microRNAs: new biomarkers in diagnosis, prognosis and
treatment of cancer. Int J Oncol. 2012;41:1897–912.
26. Weber JA, Baxter DH, Zhang S, Huang DY, Huang KH, Lee MJ, et al. The
microRNA spectrum in 12 body fluids. Clin Chem. 2010;56:1733–41.
27. De Guire V, Robitaille R, Tétreault N, Guérin R, Ménard C, Bambace N, et al.
Circulating miRNAs as sensitive and specific biomarkers for the diagnosis
and monitoring of human diseases: promises and challenges. Clin Biochem.
2013;46:846–60.28. Scheibner KA, Teaboldt B, Hauer MC, Chen X, Cherukuri S, Guo Y, et al. MiR-27a
functions as a tumor suppressor in acute leukemia by regulating 14-3-3θ.
PLoS One. 2012;7:e50895.
29. Chin D, Boyle GM, Porceddu S, Theile DR, Parsons PG, Coman WB. Head and
neck cancer: past, present and future. Expert Rev Anticancer Ther.
2006;6:1111–8.
30. Hoffman HT, Porter K, Karnell LH, Cooper JS, Weber RS, Langer CJ, et al.
Laryngeal cancer in the United States: changes in demographics, patterns
of care, and survival. Laryngoscope. 2006;116 Suppl 111:1–13.
31. Bao L, Zhao J, Dai X, Wang Y, Ma R, Su Y, et al. Correlation between miR-23a
and onset of hepatocellular carcinoma. Clin Res Hepatol Gastroenterol.
2014;38:318–30.Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
